COVID-19 Antivirals: Decision tree to support clinicians on whether COVID-19 antivirals are funded.
75 or older
0
0
Between 65 and 74
Between 65 and 74
2
Between 50 and 64
0
Between 50 and 64
3
Less than 50
3
4
Yes
Yes
Yes
Māori or Pacific peoples
The blue circles say how many high-risk medical conditions the person needs to access funded COVID-19 antivirals. High-risk medical conditions are defined by the Ministry of Health
d.
Is the patient either immunocompromised d or aged 75 or over?
No
No
Yes
b. c.
No
The patient qualifies for funded COVID-19 antivirals
How old is the patient?
If considering nirmatrelvir with ritonavir or molnupiravir. If considering remdesivir. Supplemental oxygen to maintain oxygen saturation >93% or at or above baseline for patients with chronic resting hypoxia. As per Ministry of Health criteria of ‘severe immunocompromise’ for third primary dose of COVID-19 vaccine.
Access criteria as of 18 July 2022. This criteria is subject change and regularly reviewed. Check the Pharmac website for the full access criteria.
Does the patient have any of the following? • Down syndrome • sickle cell disease • a previous admission to ICU directly as a result of COVID-19
Yes
Has the patient completed a primary course of vaccination?
a.
Yes
Patient requires supplemental oxygenc
0
How old is the patient?
No
The patient does not qualify for funded COVID-19 antivirals
No
Did the symptoms start less than 5 days a or 7 daysb ago
75 or older
Less than 50
Does the patient have confirmed or probable symptomatic COVID-19?
Yes
No
Is the patient Māori or of Pacific ethnicity?
No
Other ethnicities Has the patient completed a primary course of vaccination?
Yes
No
How old is the patient?
Less than 50
5
Between 50 and 64
4
Between 65 and 74
75 or older
How old is the patient?
Less than 50
4
Between 50 and 64
3
Between 65 and 74
0
75 or older
0
3 0